nach oben

Medical Oncology

Erschienen in:

01.09.2012 | Review Article

Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity

verfasst von: Semra Paydas

Erschienen in: Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Angiogenesis is the new blood vessels formation and is the critical event for the growth of malignant diseases and plays a key role in the development, invasion, and metastasis of malignant tumors. Epstein-Barr virus (EBV) is an important carcinogen causing to the some neoplastic disorders and lytically infected cells may contribute to the growth of EBV-associated malignancies, and this phenomenon is related with enhancing angiogenesis. Due to the strong cross-talk between angiogenesis and viral carcinogenesis and increased information about the angiogenesis and viral carcinogenesis in lymphomas, we need new therapeutic approaches to cases with lymphoma. Due to the strong cross-talk between angiogenesis and viral lymphomagenesis, this association was reviewed in this study.

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.PubMedCrossRef

Ganjoo K. Antiangiogenesis: a new approach to the treatment of lymphoma. Leuk Lymphoma. 2007;48:454–5.PubMedCrossRef

Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogensis and metastasis. Am J Hematol. 2010;85:593–8.PubMedCrossRef

Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Bar virus (EBV)-positive diffuse large B-cell lymphoa: comparison between EBV (+) and EBV (−) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233–40.PubMedCrossRef

Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Ohshima K, Suziyama J, Nakamura N, Abe M, Ichimura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya Y, Kinoshita T, Nakamura S. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124–32.PubMedCrossRef

Hong GK, Kumar P, Wang L, Damania B, Gulley ML, Delecluse HJ, Polverini PJ, Kenney SC. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol. 2005;79:13984–92.PubMedCrossRef

Siu LL, Chan JK, Kwang YL. Natural killer cell malignancies: clinicopathological and molecular features. Histol Histopathol. 2002;17:539–54.PubMed

Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, Cesarmen E. Epstein Barr virus latent gene expression in primary effusion lymphomas containing Kaposi’s sarcoma-associated herpes virus/human herpesvirus-8. Blood. 1997;90:1186–91.PubMed

Middldorp JM, Brink AATP, van den Brule AJC, Meijer CJLM. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003;45:1–36.CrossRef

10.

Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, Dörffel W. Impact of latent Epstein-Barr virus infection in adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4048–56.PubMedCrossRef

11.

Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood. 2007;110:972–8.PubMedCrossRef

12.

Oyama T, Ichimura K, Suzuki R, Suzimiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, Kagami Y, Ogura M, Saito H, Morishima Y, Nakamura S. Senile EBV + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27:16–26.PubMedCrossRef

13.

Wong HH, Wang J. Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly. Leuk Lymphoma. 2009;50:335–40.PubMedCrossRef

14.

Paydas S, Ergin M, Erdogan S, Seydaoglu G. Prognostic significance of EBV-LMP-1 and VEGF-A expressions in non-Hodgkin’s lymphomas. Leuk Res. 2008;32:1424–30.PubMedCrossRef

15.

Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Prognostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leuk Res. 2009;33:1627–35.PubMedCrossRef

16.

Abramsson A, Lindblom P, Betsholtz C. Endothelial and nonendolthelial sources of PDGF-B regulate pericyte and influence vascular pattern formation in tumors. J Clin Invest. 2003;112:1142–51.PubMed

17.

Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S. Cytokine-mediated development of SDF-1 induces revascularization through recruitment of CXCR4 + hemangiocytes. Nat Med. 2006;12:557–67.PubMedCrossRef

18.

Ruan J, Hajjar K, Rafii S, Leonard JP. Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Ann Oncol. 2009;20:413–24.PubMedCrossRef

19.

Salven P, Orpano A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF, and b FGF is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma: a single center study of 200 patients. Blood. 2000;96:3712–8.PubMed

20.

Jorgensen JM, Sorensen F, Bdix K, Nielsen JL, Olsen ML, Funder AMD, D’Amore F. Angiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584–95.PubMedCrossRef

21.

Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol. 2003;45:227–44.PubMedCrossRef

22.

Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VGEF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44:2089–93.PubMedCrossRef

23.

Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RH, Hammer AS, Hamilton-Dutoit S, Natkunam Y. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B cell lymphoma subtypes. Am J Pathol. 2007;170:1362–9.PubMedCrossRef

24.

Niitsu N, Okamoto M, Nakamine H, Yoshino T, Tamaru J, Nakamura S. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in non-Hodgkin’s lymphoma. Eur J Hematol. 2002;68:91–100.CrossRef

25.

d’Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS. Epstein-Barr virus genome in non-Hodgkin’s lymphomas occurring in immunocompetent patients: highset prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood. 1996;87:1045–55.PubMed

26.

Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3):972–8.PubMedCrossRef

27.

Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma: comparison between EBV (+) and EBV (−) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233–40.PubMedCrossRef

28.

Morales D, Beltran B, De Mendoza FH, Riva L, Yabar A, Quinones P, Butera JN, Castillo J. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(1):66–72.PubMedCrossRef

29.

Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol. 2009;40(5):653–61.PubMedCrossRef

30.

Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41(3):352–7.PubMedCrossRef

31.

Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.PubMedCrossRef

32.

Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation. 2007;83(8):1114–21.PubMedCrossRef

33.

Holtan SG, Porrata LF, Colgan JP, et al. mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD). Am J Hematol. 2008;83(8):688–9.PubMedCrossRef

34.

Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ. Expression of protease receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract. 2009;205:542–50.PubMedCrossRef

35.

Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its to EBV status. Virus Res. 2006;115:85–90.PubMedCrossRef

36.

Murano S, Inoue Hİ, Tanabe T, Joab I, Yoshizaki T, Furukawa M, Pagano JS. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane proetin 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. PNAS. 2001;98:6905–10.CrossRef

37.

38.

Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature. 2000;407:249–57.PubMedCrossRef

39.

Yoshizaki T, Horikawa T, Quing-Chun R, Wakasaka N, Takeshita H, Sheen TS, Lee SY, Sato H, Furukawa M. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001;7:1946–51.PubMed

40.

Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein-1induces synthesis of hypoxia inducible factor 1 alpha. Mol Cell Biol. 2004;24:5223–34.PubMedCrossRef

41.

Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS. Epstein Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res. 2002;62:6337–44.PubMed

42.

Chabner BA, Koop E, Niederhuber JE, Pinedo HM. Homage to Judah Folkman. Oncologist. 2008;13:205–11.CrossRef

43.

Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006;24:1712–9.PubMedCrossRef

44.

Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma. 2009;50:728–35.PubMedCrossRef

45.

Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ. Rituximab, Bevaciumab and CHOP (RA-CHOP) in untreated diffuse large B cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005.PubMedCrossRef

46.

Shimoyama Y, Asano N, Kojima M, Morishima S, Yamamoto K, Oyama T, Kinoshita T, Nakamura S. Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic aproach to a newly recognized clinicopathological entity. Patol Internat. 2009;59:835–43.CrossRef

47.

Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, Cheson BD. Cancer and leukemia group B. Thalidomide has limited single-agent activity in relapsed or refractory non-Hodgkin’s lymphomas: a phase II trial of the cancer and leukemia group B. Br J Haematol. 2008;140:313–9.PubMedCrossRef

48.

Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, Elstrom R, Lachs M, Hajjar KA, Leonard JP. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655–64.PubMedCrossRef

49.

Czucman MS, Reeder CB, Palikoff J,. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26 (Abstr 8509).

50.

Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y. Kerbel RS Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–6.PubMed

51.

Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, George P, Kaufman TP, Leonard JP. The PEP-C (prednisone, etoposide, prcarbazine, and cyclophosphamide) regimen for relapsing/refractory lymphoma: low dose metronomic, multidrug therapy. Cancer. 2008;112:2228–32.PubMedCrossRef

52.

Buckstein R, Meyer RM, Seymour L, Biagi J, Mackay H, Laurie S, Eisenhauer E. Phase II testing of sunitinib: the national cancer institute of Canada clinical trials group IND program trials IND 182–185. Curr Oncol. 2007;14:154–61.PubMedCrossRef

53.

Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, Lacasce AS, Elstrom R, Coleman M, Leonard JP. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 (Epub ahead of print).

54.

Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–56.PubMedCrossRef

55.

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.PubMedCrossRef

56.

Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL. Bevacizumab potentiates chemotherapeutic affect of T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica. 2011;96:927–31.PubMedCrossRef

57.

Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol. 2008;6:899–909.PubMed

58.

Paydas S. Anti-angiogenic strategies will be a revolution in lymphoma? Leuk Res. 2010;34:552.PubMedCrossRef

Titel: Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity
verfasst von: Semra Paydas
Publikationsdatum: 01.09.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-0065-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function

Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement

Erratum to: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer

Polymorphism in pre-miR-30c contributes to gastric cancer risk in a Chinese population

Absence of human papillomavirus sequences in epithelial breast cancer in a Mexican female population

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie